DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the JUBILANT PHARMOVA LTD (JUBLPHARMA) share price today?

JUBILANT PHARMOVA LTD (JUBLPHARMA) is trading at ₹1,022.6 on the NSE, up 0.19% on the day. Source: DocStoX.

What is the PE ratio of JUBILANT PHARMOVA LTD?

JUBILANT PHARMOVA LTD has a price-to-earnings (PE) ratio of 40.9 in the Healthcare sector.

What is the market capitalisation of JUBILANT PHARMOVA LTD?

JUBILANT PHARMOVA LTD has a market capitalisation of approximately ₹16,228 crore.

JUBILANT PHARMOVA LTD

JUBLPHARMA·NSE·Healthcare

₹1,022.60▲ +1.90 (+0.19%)

Healthcare · Pharmaceuticals

A steady, established business

NIFTY 500NIFTY SMALLCAP 250

Day₹1005.05

₹1027.00

52W₹786

₹124851%

Open

₹1017.00

High

₹1027.00

Low

₹1005.05

Prev Close

₹1020.70

Volume

1.06L

VWAP

₹1016.15

Snapshot

Key fundamentals

Market Cap

₹16,228 Cr

P/E Ratio

40.87Expensive

P/B Ratio

2.19

EPS

₹25.02

Book Value

₹445.00

ROE

6.55%Weak

ROCE

9.00%Weak

Dividend Yield

0.52%

Debt / Equity

0.51Moderate

Face Value

₹1.00

52W High

₹1248.00

52W Low

₹786.05

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatMedium uncertainty

Fair value estimate

₹431

▼ 57.9%downside

Trading at ₹1,023 — 58% above our estimate

BearFair valueBull

₹366₹431₹501

/100

Business quality — Watch the fundamentals

Growth 39Profitability 12Efficiency 3Valuation 49

Plain English

Our view

A steady, established business
Weak returns on equity (7%)

Risks

Weak returns on equity (7%)
Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

7% ROE fading to 13% over ~3 yrs, on ₹445 book

₹411

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹501

Analyst target

No analyst coverage

—

Blended fair value₹431

What the numbers say

Investment thesis

Bull case

No standout positives from the current metrics.

Bear case

Weak returns on equity (7%)
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

40.9Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

6.5%Weak

Above 15% is considered healthy for Indian equities

ROCE

9.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.51Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹16,228 Cr

P/B

2.19

EPS

₹25.02

Div Yield

0.52%

What changed

Recent changes

Domestic institutions+0.4% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 40.9×

Growth

Steady

+10% rev CAGR

Profitability

Modest

6.5% ROE

Financial health

Comfortable

D/E 0.51

Momentum

N/A

No technicals

Today

Trading activity

Delivery %43.9%

Turnover₹1080.33L Cr

Trades12,433

VWAP₹1016.15

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+9.6%

+6.3%

10Y

+3.7%

Profit

—

-13.8%

10Y

+0.3%

EPS

—

-13.8%

10Y

+0.2%

Profile

Pros

Company has been maintaining a healthy dividend payout of 43.9%
Company's working capital requirements have reduced from 28.6 days to 13.4 days

Watch-outs

Cons

The company has delivered a poor sales growth of 6.31% over past five years.
Company has a low return on equity of 5.80% over last 3 years.
Company might be capitalizing the interest cost
Promoter holding has decreased over last 3 years: -3.01%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Domestic institutions added 0.40 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

48%

Promoter

Promoters

47.7%0.00

Public

17.6%-0.28

FII / FPI

15.9%-0.06

DII

11.6%+0.40

Others

7.2%

Total shareholders

86,347-3,786 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter47.68%

FII15.90%

DII11.62%

Public17.57%

Others7.23%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]